1          Treatment with Bay K8644, an L-type calcium channel agonist, also significantly increased th

2 tion of similar behavior with another L type calcium channel agonist, and the protection afforded by

3  currents are substantially increased by the calcium channel agonist Bay K 8644 and inhibited by the

4                    Application of the L-type calcium channel agonist Bay K 8644 or activation of NMDA

5 elevated extracellular potassium or with the calcium channel agonist Bay K 8644 protected neurons.

6                       Conversely, the L-type calcium channel agonist Bay K8644 induced stereotypic to

7                                   The L type calcium channel agonist (+/-)Bay K 8644 has been reporte

8                               Pacing and the calcium channel agonist BAYK 8644 activated c-Jun N-term

9 mutTARDBP results in defective NMJs and that calcium channel agonists could be novel therapeutics for

10                                The lack of a calcium channel agonist (e.g., BayK8644) for CaV2 channe

11  To further verify the mechanism, the L-type calcium channel agonist FPL 64176 was administered to pr

12  chronic treatment with either of the L-type calcium channel agonists FPL 64176 or Bay K 8644.

13 provoked by administration of another L type calcium channel agonist, FPL 64176.

14 nown actions of (+/-)Bay K 8644 as an L type calcium channel agonist, the reproduction of similar beh